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This paper describes a case of early (7 months after transplant) cardiac allograft vasculopathy. This-43-year-old (CMV positive,
EBV negative) female patient underwent an orthotopic heart transplant with a (CMV negative, EBV positive) donor heart. She
had a history of herpes zoster infection and postherpetic neuralgia in the past. The patient’s panel reactive antibodies had been
almost undetectable on routine surveillance testing, and her surveillance endomyocardial biopsies apart from a few episodes of
mild-to-moderate acute cellular rejection (treated adequately with steroids) never showed any evidence of humoral rejection. The
postoperative course was complicated by multiple admissions for upper respiratory symptoms, and the patient tested positive
for entero, rhino, and coronaviruses serologies. During her last admission (seven months postoperatively) the patient developed
mild left ventricular dysfunction with an ejection fraction of 40%. The patient’s endomyocardial biopsy done at that time
revealed concentric intimal proliferation and inﬂammation resulting in near-total luminal occlusion in the epicardial and the
intramyocardial coronary vessels, suggestive of graft vasculopathy with no evidence of rejection, and the patient had a fatal
ventricular arrhythmia.
1.Introduction
Cardiac transplantation is a well-deﬁned therapy for end-
stage heart failure. Following transplantation, median survi-
val is 10 years rising to 13 years for those who survive the
ﬁrst year [1]. The leading causes of death in the ﬁrst year fol-
lowing transplantation include infection, rejection, and graft
failure. Cardiac allograft vasculopathy (CAV) is the second
leading cause of death after 1 year following transplantation,
second only to malignancy [1].
We present a case of early (7 months after transplant)
cardiac allograft vasculopathy (CAV) in a cytomegalovirus
(CMV) positive patient with a history of herpes zoster infec-
tion and multiple other viral infections in the postoperative
course possibly contributing to graft vasculopathy.
2.Case
A 43-year-old Caucasian female with a history of nonis-
chemic dilated cardiomyopathy with left ventricular ejection
fraction (LVEF) of 10–15% status following Thoratec Heart-
Mate II left ventricular assist device (LVAD) (implanted 2
years prior as a Bridge to Transplant) was transferred to
our tertiary care facility for management of unresolving
pseudomonas driveline infection. The patient secondary to
persistent pseudomonas bacteremia despite adequate treat-
ment with intravenous antibiotics underwent LVAD removal
with reimplantation with another VAD. The patient also
u n d e r w e n ta nA I C Dl e a de x t r a c t i o nw i t hg e n e r a t o rc h a n g e
secondary to questionable vegetation on the deﬁbrillator
lead on transesophageal echocardiogram. The patient did
well following that and remained home for 4 months
while awaiting a cardiac transplant. Her past history was
signiﬁcant for hypertension, dyslipidemia, recurrent pul-
monary embolism, history of herpes zoster infection with
postherpetic neuralgia, and intracerebral hemorrhage.
Four months later the patient was electively admitted
for transplant evaluation. Her panel reactive antibody (PRA)
levelswerefoundtobelowat4%asmeasuredbyﬂowcytom-
etry using HLA class I Luminex-coated beads. The patient
(CMV positive) ﬁnally underwent a CMV negative, Epstein-
Barr virus (EBV) positive orthotopic heart transplant with-
out the need for desensitization. The patient’s immediate2 Case Reports in Medicine
Table 1: Viral titres and lab data before and after transplant.
Pretransplant 3 months after 6 month after
transplant transplant
CMV IgG 3.56 NA Undetectable
EBV IgG >1.09 NA NA
VZV IgG 5.04 NA NA
Glucose (mg/dL) 122 154 150
Total cholesterol 185 200 190
(mg/dL)
LDL-C (mg/dL) 123 125 120
HDL-C (mg/dL) 32 30 32
TG (mg/dL) 149 168 160
CMV: cytomegalovirus, EBV: Epstein-Barr virus, HDL: high-density lipop-
rotein, IgG: immunoglobulin G, NA: data not available, LDL: low-density
lipoprotein, TG: triglyceride, VZV: varicella zoster virus (normal values for
all viral titres: <0.90 in our laboratory).
postoperative course was complicated by multiple failed
attempts at extubation secondary to ﬂuid overload that
required tracheostomy and acute kidney injury requiring
temporary hemodialysis (with complete eventual recovery of
renalfunction).Thepatientafter4weeks,onroutinesurveil-
lance endomyocardial biopsy (EMB), was found to have
ISHLT grade 2R acute cellular rejection which was success-
fully treated with intravenous pulsed steroids and mycophe-
nolatemofetil.Thepatientwaseventuallydischargedhome2
weeks later and was followed as an outpatient. Three months
subsequent to transplant the patient started to develop signs
andsymptomsofupperrespiratorytractinfectionsmanifest-
ing as unremitting cough. The patient admitted was found to
have viral infection with positive serologies for entero, rhino,
and coronaviruses, and the EMB was negative for rejec-
tion. The patient was managed conservatively without any
antiviral treatment except prophylactic ganciclovir for CMV
prophylaxis and discharged home. The patient did present
again with similar respiratory symptoms a month later at
which time it was decided to treat the patient with a course
of oseltamivir (Tamiﬂu) for a clinical suspicion of inﬂuenza.
The patient was discharged only to be readmitted 2 months
later (6 months after transplant) for symptoms of exertional
dyspnea,nausea,andabdominalpain.Thepatientwasfound
to have low cardiac index (1.59 L/min/m2) and elevated
right sided pressures on right heart catheterization while the
EMBremained negativeforcellularorhumoralrejection. An
echocardiogram at the time revealed a mildly depressed left
ventricularejectionfractionat40%withmildrightventricu-
lar dysfunction. The patient’s panel reactive antibodies were
undetectable. Table 1 lists the trends in the available viral
titres and other laboratory data (glucose and lipids). The
patient was treated with intravenous methylprednisolone
and plasmapheresis to treat for possible graft dysfunction.
The next day the patient had a sudden cardiorespiratory
arrest and died despite prolonged attempts at resuscitation.
A postmortem analysis revealed microscopic changes of
concentric intimal proliferation and inﬂammation resulting
in near-total luminal occlusion in the epicardial and the
intramyocardial coronary vessels, suggestive of graft vas-
culopathy (Figures 1(a)–1(c)). There was no evidence of
rejection seen.
3. Discussion
Cardiactransplantationisthedeﬁnitivetreatmentforeligible
patients with end-stage heart failure. CAV and graft failure
are the leading cause of death in patients who survive the
ﬁrst year after transplant. Despite a small decrease in the
cumulative incidence documented recently, the incidence of
CAV after transplant remains signiﬁcant: 8% at 1 year, 20%
at 3 years, 30% at 5 years, and more than 50% at 10 years
[1]. CAV is a risk factor for long-term mortality, but the
diagnosis of CAV also carries a short-term mortality risk—
approximately 10% of patients die in the 12 months after the
diagnosis CAV [1].
The diagnosis of CAV is challenging because of dein-
nervation as well as the concentric and diﬀuse nature of
the disease. Classical symptoms of angina are often missing,
and patients tend to present with heart failure [2]. There
are multiple purported etiologies for graft coronary artery
disease including both immunologic and nonimmunologic
factors. Immunologic factors include human leukocyte anti-
gen mismatching, cytokine production, and activation of the
cellular immune system. Nonimmunologic factors include
diabetes, hypertension, and hyperlipidemia [3, 4]. There is
also accumulating data suggesting that infections play a role
in atherosclerosis and in CAV.
CMVisoneofthepathogensthathasbeenmostconvinc-
ingly implicated in the pathophysiology of CAV [5]. Viral
infections including those due to CMV have been associated
with accelerated CAV [6, 7]. Positive pretransplantation
CMV serology has been shown to be a risk factor for CAV in
children [8, 9]. Cardiovascular risk has also been associated
with seropositivity for Chlamydia pneumonia, Helicobacter
pylori,CMV ,andotherherpesviruses.H o wev er ,mor er ecent
studies in larger patient cohorts have demonstrated only
modest associations [10, 11]. Given the modest and variable
risk that has been linked to individual pathogens, Zhu and
colleagues have proposed the sum of the relevant infectious
agents, deﬁned as the “total pathogen burden,” as the impor-
tant risk factor to be considered. Exposure to a panel of ﬁve
pathogenswasfoundtobepredictiveofangiographicdisease
[12] and cardiovascular events [13]. Similar results were
reported in a study showing that exposure to increasing
numberofpathogenswasassociatedwithincreasedrisk[14].
An increasing “pathogen burden” deﬁned as the aggregate
number of positive serologies (mainly driven by burden of
Herpesviridae) was signiﬁcantly predictive of the long-term
prognosis in a doseresponse manner. These observations
have led the investigators to propose the “Herpes Burden”
(aggregate seropositivity to CMV, herpes simplex-1 and -2,
and EBV) as a more eﬀective predictor of cardiovascular risk
[14]. Our patient had a CMV positive status who received an
EBVpositivedonorheartalongwithahistoryofdocumented
herpes zoster infection in the past. Whether the multiple
serologically positive viral infections (entero, rhino, and
coronaviruses) amongst the many other nonimmune factorsCase Reports in Medicine 3
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Figure 1:Endomyocardialbiopsy7monthsaftertransplantshowinggraftvasculopathy.Endomyocardialbiopsydemonstratingmicroscopic
changes of concentric intimal proliferation and chronic inﬂammation resulting in near-total luminal occlusion in the epicardial and the
intramyocardial coronary vessels, suggestive of graft vasculopathy. Hematoxylin and eosin stain: (a) low power, (b) high power, and (c) C4d
immunostaining. Immunoperoxidase with C4d monoclonal antibody negative.
augmentedtheexistentviralburdentherebytriggeringaself-
perpetuating immune cascade, inducing inﬂammation and
intimal proliferation, is a concept that can only be hypothe-
sized and arduous to prove. Kumar et al. in their prospective
study of 93 lung transplant recipients recently demonstrated
acute rejection (≥grade 2 ISHLT) in 33.3% (16/48) patients
within 3 months of respiratory viral infections (RVIs) as
opposed to only 6.7% (3/45) in RVI negative patients. Sixty-
two percent of these patients with history of RVIs progressed
to obliterative bronchiolitis (chronic airway rejection) on
biopsies done within 1 year [15]. This study adds to the
increasing evidence highlighting a possible immunogenic
potential of respiratory viruses in solid organ recipients
manifesting as acute or chronic rejection.
Treatment of established CAV has been disappointing.
The options have included adjusting the immunosuppres-
sive regimen, percutaneous or surgical revascularization or
retransplantation.BecauseCAVhassuchanimportantinﬂu-
ence on morbidity and mortality, it is evident that if further
improvement in graft and patient survival is to be made,
attention must focus on reducing the risk of CAV. There is
proven beneﬁt from lipid lowering therapy, mammalian
target of rapamycin (mTOR) inhibitors (everolimus and
sirolimus), and possibly diltiazem (calcium channel blocker)
[4].
Our case is an addition to a list of very limited number
of cases of early allograft vasculopathy (within the ﬁrst year
after transplant) that aims to highlight its poor clinical
outcome and survival compared to the form that develops
after the ﬁrst year. The lack of data on the patients viral titres
is an important limitation of this case. Allograft coronary
disease remains one of the greatest obstacles to long-term
recipient survival after cardiac transplantation. This process
has been extensively studied, yet remains poorly understood.
Althoughittypicallybecomesclinicallysigniﬁcantyearsafter
transplantation, it can also occur early and result in recipient
death as early as 6 months following transplant. Why a given
patient develops an aggressive form of the disease early after
transplantation and another patient may live ten or even
twenty years without evidence of clinically signiﬁcant disease
is unknown.
Conﬂict of Interests
The authors of this paper declare that they have no conﬂict
of interests. Furthermore, no commercial organization took
part in its preparation or funding.4 Case Reports in Medicine
References
[1] J. Stehlik, L. B. Edwards, A. Y. Kucheryavaya et al., “The Reg-
istry of the International Society for Heart and Lung Trans-
plantation: twenty-seventh oﬃcial adult heart transplant
report—2010,” Journal of Heart and Lung Transplantation, vol.
29, no. 10, pp. 1089–1103, 2010.
[2] Q. Cai, U. C. Rangasetty, A. Barbagelata, K. Fujise, and M. M.
Koerner, “Cardiac allograft vasculopathy: advances in diagno-
sis,” Cardiology in Review, vol. 19, no. 1, pp. 30–35, 2011.
[3] M. Kass and H. Haddad, “Cardiac allograft vasculopathy:
pathology, prevention and treatment,” Current Opinion in
Cardiology, vol. 21, no. 2, pp. 132–137, 2006.
[4] D. Schmauss and M. Weis, “Cardiac allograft vasculopathy:
recent developments,” Circulation, vol. 117, no. 16, pp. 2131–
2141, 2008.
[5] H. A. Valantine, “The role of viruses in cardiac allograft vas-
culopathy,” American Journal of Transplantation, vol. 4, no. 2,
pp. 169–177, 2004.
[6] J. A. Graham, R. A. Wilkinson, T. Hirohashi et al., “Viral
infection induces de novo lesions of coronary allograft vas-
culopathy through a natural killer cell-dependent pathway,”
American Journal of Transplantation, vol. 9, no. 11, pp. 2479–
2484, 2009.
[7] L. Potena, F. Grigioni, G. Magnani et al., “Prophylaxis versus
preemptive anti-cytomegalovirus approach for prevention of
allograft vasculopathy in heart transplant recipients,” Journal
of Heart and Lung Transplantation, vol. 28, no. 5, pp. 461–467,
2009.
[8] T. Hussain, M. Burch, M. J. Fenton et al., “Positive pretrans-
plantation cytomegalovirus serology is a risk factor for cardiac
allograft vasculopathy in children,” Circulation, vol. 115, no.
13, pp. 1798–1805, 2007.
[9] W. T. Mahle, M. T. Fourshee, D. M. Naftel et al., “Does cyto-
megalovirus serology impact outcome after pediatric heart
transplantation?” J o u r n a lo fH e a r ta n dL u n gT r a n s p l a n t a t i o n ,
vol. 28, no. 12, pp. 1299–1305, 2009.
[10] J. Danesh, “Coronary heart disease, Helicobacter pylori,d e n t a l
disease, Chlamydia pneumoniae, and cytomegalovirus: meta-
analyses of prospective studies,” American Heart Journal, vol.
138, no. 5, pp. S434–S437, 1999.
[11] J. Danesh, P. Whincup, M. Walker et al., “Chlamydia pneumo-
niae IgG titres and coronary heart disease: prospective study
and meta-analysis,” BMJ, vol. 321, no. 7255, pp. 208–213,
2000.
[12] J. Zhu, A. A. Quyyumi, J. E. Norman et al., “Eﬀects of total
pathogen burden on coronary artery disease risk and C-
reactiveproteinlevels,”AmericanJournalofCardiology,vol.85,
no. 2, pp. 140–146, 2000.
[13] J.Zhu,F.J.Nieto,B.D.Horne,J.L.Anderson,J.B.Muhlestein,
and S. E. Epstein, “Prospective study of pathogen burden and
risk of myocardial infarction or death,” Circulation, vol. 103,
no. 1, pp. 45–51, 2001.
[14] H. J. Rupprecht, S. Blankenberg, C. Bickel et al., “Impact of
viral and bacterial infectious burden on long-term prognosis
in patients with coronary artery disease,” Circulation, vol. 104,
no. 1, pp. 25–31, 2001.
[15] D. Kumar, S. Husain, M. H. Chen et al., “A prospective
molecular surveillance study evaluating the clinical impact
of community-acquired respiratory viruses in lung transplant
recipients,” Transplantation, vol. 89, no. 8, pp. 1028–1033,
2010.